FDA Advisory Board Recommends Moderna Booster Shot Be Approved
A Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna booster shots for emergency use authorization, bringing millions of Americans one step closer to being eligible for an additional dose. The panel, called the Vaccine and Related Biological Products Advisory Committee, voted unanimously in favor of authorizing the shots.
The decision will now go to the FDA, which is expected to make a final ruling in the coming days.
The advisory panel’s recommendations for the Moderna booster followed the blueprint it established last month for booster shots of Pfizer-BioNTech’s vaccine: It would be authorized for adults ages 65 and up; people in long-term care facilities; people with underlying medical conditions; and people at high risk of exposure to the coronavirus because of their job. These individuals would be eligible at least six months after their second shot.
WASHINGTON (AP) — US advisory panel endorses Moderna COVID-19 vaccine booster shots for seniors and other high-risk groups.
— Kyle Griffin (@kylegriffin1) October 14, 2021
Moderna’s booster dose would be given as a half dose of 50 micrograms, compared to the original 100 micrograms given in the initial vaccination series. By contrast, Pfizer’s booster is the same 30 microgram dosage as its initial series.
Maderna is literally what my Grandma Dorothy called Madonna in the 80s https://t.co/MAJtloLIaG
— T👻r👻 D🐈⬛bl💀n 🎃🧙🏻♀️ (@taradublinrocks) September 1, 2021
Moderna’s booster dose would be given as a half dose of 50 micrograms, compared to the original 100 micrograms given in the initial vaccination series. (By contrast, Pfizer’s booster is the same 30 microgram dosage as its initial series.)
— Matthew Herper (@matthewherper) October 14, 2021
Data showed that protection from Moderna’s vaccine has waned: People who were vaccinated earlier in the year were more likely to have a breakthrough infection compared to people who received their vaccinations several months later. Nearly all of these breakthrough infections were caused by the delta variant. The booster dose led to higher antibody levels, including antibodies against the delta variant.
As a Moderna guy, I’m so ready for my booster. I’m really hoping the FDA and CDC approve that Moderna booster soon.
Who’s with me? https://t.co/LRIsrKdYIL
— Robert Garcia (@RobertGarcia) October 7, 2021
The same group of advisers will convene Friday to discuss a booster shot of Johnson & Johnson’s Covid vaccine. It will also review the results of a National Institutes of Health (NIH) study on “mixing and matching” Covid vaccines. That study found that giving people who initially received the Johnson & Johnson vaccination a booster dose of either Pfizer or Moderna led to a stronger immune response than a second Johnson & Johnson dose.
As a woman under 50 who received the J&J vaccine, I will not get a J&J booster. There are other options, specifically Pfizer and Moderna, that are not associated with the very rare but very serious blood clotting disorder in younger women. FDA & CDC should allow “mix & match”. pic.twitter.com/gPdnxQUwbF
— Leana Wen, M.D. (@DrLeanaWen) October 9, 2021
Next week, a group of advisers to the Centers for Disease Control and Prevention (CDC) will take up the question of who should receive the Moderna and Johnson & Johnson booster shots. If the boosters are recommended, CDC Director Dr. Rochelle Walensky would then sign off, and shots could start going into arms.